SAN DIEGO–(BUSINESS WIRE)–Kurin Inc., the inventor and manufacturer of Kurin® blood culture
collection sets, responded to a patent-infringement lawsuit brought
against Kurin by Magnolia Medical.
With its innovative design the Kurin Lock® has been a disruptive
technology in the market, allowing Kurin to quickly engage hospitals
that prefer its FDA 510(k) cleared device. With a small, intuitive
design, the Kurin Lock is easy to use and suitable for a wide range of
applications, including pediatrics. From the beginning, Magnolia
attacked Kurin’s design claiming that it did not divert enough volume or
sufficiently isolate diverted blood. Now that the Kurin Lock has been
proven in clinical use and hospitals are switching from Steripath to the
Kurin Lock, Magnolia is claiming patent infringement.
“The timing of this suit is not a coincidence,” said Bob Rogers, CEO of
Kurin and inventor of the Kurin Lock. “For years, Magnolia has sold
their Steripath product without FDA clearance. It is a large, cumbersome
device that is not intuitive, and is unsuitable for use in pediatrics,
so it is not surprising that Magnolia has failed to gain market
Despite their prior claims that the Kurin Lock design is ineffective,
Magnolia now asserts that it invented the Kurin device. “It is
illogical. Why would Magnolia launch and continue to sell their Rube
Goldberg contraption if they had conceived the simple, intuitive design
of the Kurin Lock?” asked Rogers.
Continuing, Rogers said, “We respect the intellectual property rights of
others. The U.S. Patent Office has found the design of the Kurin Lock to
be novel when compared to Magnolia’s patents, and worthy of patent
protection. The Kurin Lock does not infringe any Magnolia patent and we
are confident that this position will be proven in court. Our team has
significant resources and a track record of success in patent litigation
to see this baseless suit through, however long it takes.”
About Kurin Inc.
Kurin Inc., a certified Minority Business Enterprise (MBE), is focused
on the design, development, manufacture, marketing, and sale of products
that help healthcare providers reduce contaminated blood cultures. San
Diego-based Kurin has received FDA 510(k) market clearance. For more
information, visit the website at www.kurin.com.